Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | Therapeutic options following failure to JAK inhibitors

Ciro Rinaldi • 6 Jun 2022
ASCO 2022
Essential Thrombocythemia Myelofibrosis Myeloproliferative Neoplasms Rare Diseases Fedratinib Momelotinib Pacritinib Ruxolitinib Selinexor
MOMENTUM

Ciro Rinaldi, MD, PhD, Lincoln County Hospital, Lincoln, UK, reflects on therapeutic approaches for patients with myelofibrosis (MF) who have progressed on Janus kinase (JAK) inhibitors. Following progression on ruxolitinib, next-generation JAK inhibitors such as fedratinib may improve outcomes, as well as combination approaches with other targeted therapies, such as selinexor. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Ciro Rinaldi

1:12
The potential of targeting mutant calreticulin with antibodies in MPNs
Ciro Rinaldi • 3 Jun 2023
0:58
The potential of CAR-T therapy targeting mutant CALR in myelofibrosis & essential thrombocythemia
Ciro Rinaldi • 3 Jun 2023
1:22
Benefits and drawbacks of the IPSS-M
Ciro Rinaldi • 5 May 2023
1:31
HMA combination strategies in MDS: BLC2, CD47 & TIM-3 inhibitors
Ciro Rinaldi • 5 May 2023

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals